Clinical Trial Update: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 neoadjuvant trial is evaluating PD-1 blockade plus TIGIT blockade in cisplatin-ineligible operable high-risk urothelial carcinoma; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• PD-1 inhibitor
• TIGIT inhibitor

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Malignancy | Phase 1, Phase 2 | Status: RECRUITING